Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
Patents for C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom (107,979)
11/2005
11/16/2005EP1594502A1 4- (2,4-dichloro-5-methoxyphenyl)amino -6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
11/16/2005EP1594501A2 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
11/16/2005EP1379138B1 Liquid formulations for dermal application in treatment of parasitic insects in animals
11/16/2005EP1370557B1 Benzimidazole anti-inflammatory compounds
11/16/2005EP1363631A4 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
11/16/2005EP1317442B1 Quinolinone derivatives as tyrosine kinase inhibitors
11/16/2005EP1257550B1 Platelet adp receptor inhibitors
11/16/2005CN1697830A 嘧啶衍生物 Pyrimidine derivatives
11/16/2005CN1697650A Non-nucleoside reverse transcriptase inhibitors
11/16/2005CN1696127A Analogue of thalidomide and preparation method
11/16/2005CN1227248C Imidazolidine derivatives, their preparation, and their use as antinflamatory agent
11/16/2005CN1227247C Method for producing therapeutic agents for ulcers
11/16/2005CN1227246C Improved omeprazole preparation process and compositions thereof
11/16/2005CN1227241C Arylpiperazines having activity at the serotnin 1A receptor
11/16/2005CN1227236C Substituted imidazole neuropeptide YY5 receptor antagonists
11/16/2005CN1227234C Substituted iminoazines
11/16/2005CN1227229C Ethylene derivatives and pest controlling agents containing same
11/16/2005CN1227228C Delta 1-pyrrolines used as pesticides
11/16/2005CN1227008C Method of converting COX-2 inhibition compounds that are not COX-2 selective inhibitors to derivatives that are COX-2 selective inhibitors
11/15/2005US6965036 Intermediates for guanidine mimics as factor Xa inhibitors
11/15/2005US6965032 Substituted dihydro 3-halo-1h-pyrazole-5-carboxylates and their preparation and use
11/15/2005US6964977 E.g., 5-(((Z)-(2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl)-amino)-1,3-dihydro-2H -benzimidazol-2-one; inhibition or antagonism of protein kinases; treating pain or cancer
11/15/2005US6964974 2,3-oxidosqualene-lanosterol cyclase inhibitors
11/15/2005US6964973 Nonsteroidal agonists and antagonists
11/15/2005US6964967 Substituted pyrido[2,3-d]pyrimidines and methods for their use
11/15/2005US6964966 Such as 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-amino-3-methyl-1 -piperidinyl)-4-oxo-quinoline-3-carboxylic acid for treatment of systemic or topical infections
11/15/2005CA2330351C New linear or cyclical ureas, their preparation process and the pharmaceutical compositions which contain them
11/15/2005CA2207627C 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
11/15/2005CA2170645C Process for the preparation of n-methyl-3-(1-methyl-4-piperidinyl)-14-indole-5-ethanesulphonamide
11/10/2005WO2005105791A1 Indolyl derivatives as liver-x-receptor modulators
11/10/2005WO2005105790A1 4- 2- (cycloalkylamino) pyrimidin-4-yl ! - (phenyl) - imidazolin-2- one derivatives as p38 map- kinase inhibitors for the treatment of inflammatory diseases
11/10/2005WO2005105788A1 Indole derivatives and use thereof as kinase inhibitors
11/10/2005WO2005105787A1 Rapid and robust 3d/3d registration technique
11/10/2005WO2005105786A1 A process for preparing pyridinylmethyl-1h- benzimidazole compounds in enantiomerically enriched form or as single enantiomers
11/10/2005WO2005105785A2 Indole derivatives for treatment of obesity
11/10/2005WO2005105784A1 Diastereoselective synthesis process for the preparation of imidazole compounds
11/10/2005WO2005105783A1 Diastereoselective synthesis process with 6-bromo-4-(3-chlorophenyl)-2-methoxy-quinoline
11/10/2005WO2005105782A1 Diastereoselective addition of lithiated n-methylimidazole on sulfinimines
11/10/2005WO2005105781A1 Imidazole derivatives used as tafia inhibitors
11/10/2005WO2005105780A2 Compositions useful as inhibitors of rock and other protein kinases
11/10/2005WO2005105779A1 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor
11/10/2005WO2005105778A2 4-amino-5-cyanopyrimidine derivatives
11/10/2005WO2005105770A2 Arylphenylamino-, arylphenylamide-, and arylphenylether-sulfide derivatives
11/10/2005WO2005105760A1 Heterocyclic amide compound and use thereof as an mmp-13 inhibitor
11/10/2005WO2005105758A1 Tri-substituted ureas as cytokine inhibitors
11/10/2005WO2005105757A1 Tri-substituted ureas as cytokine inhibitors
11/10/2005WO2005105752A1 Novel phenantridine analogues and their uses as inhibitors of hyperproliferation of t cells and/or keratinocytes
11/10/2005WO2005105748A1 4-halogenalkylpyridin-3-sulphonamides, method for producing same, agents containing same, and use thereof as agents for pest control
11/10/2005WO2005105743A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof
11/10/2005WO2005105303A1 Use of metal complexes having bispyridylpyrimidine or bispyridyltriazine ligands as catalysts for reactions with peroxy compounds for bleaching coloured stains on hard surfaces
11/10/2005WO2005105301A1 Catalyst composition and production process
11/10/2005WO2005105091A1 Fluorinated 4-azasteroids as androgen receptor modulators
11/10/2005WO2005105079A2 Novel imidazoles
11/10/2005WO2005087721A3 Compounds as inhibitors of hepatitis c virus ns3 serine protease
11/10/2005WO2005082858A3 Isoquinoline derivatives
11/10/2005WO2005075429B1 Novel quinoline-carbaxamides as jack3 kinase modulators
11/10/2005WO2004099155A3 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (phenyl) amide derivates and related compounds as bradykinin b1 receptor antagonists for the treatment of inflamatory diseases
11/10/2005US20050250948 (2-Chlorophenyl)-[2-(1-isopropyl-piperidin-4-ylmethoxy)-3-methyl-3H-imidazol-4-yl]-]-methanone; histamine receptor antagonist; neurologic disorders; reacting imidazole compound with base and perhaloalkane, to form 2-haloimidazole, and with electrophile to form C-5 position substituted imidazole compound
11/10/2005US20050250945 Triazine compounds as inhibitors of bacterial type III protein secretion systems
11/10/2005US20050250829 Kinase inhibitors
11/10/2005US20050250819 Inhibitors of bacterial type III protein secretion systems
11/10/2005US20050250815 e.g. 4-Methoxy-pyrrolidine-1,2-dicarboxylic acid 1-[(4-chloro-phenyl)-amide] 2-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide}; anticoagulant, thrombolytic agent; thrombus formation within blood vessels; cardiovascular disease
11/10/2005US20050250814 Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity
11/10/2005US20050250811 Such as 14-O-[4-hydroxy-N-valyl-piperidin-3-yl]-sulfanylacetylmutilin
11/10/2005US20050250810 Screening for an enzyme inhibitor of Fab I or Fab K using providing a reaction mixture comprising Fab I or Fab K, crotonyl-ACP and NAPDH or NADH; contacting a candidate compound with the reaction mixture; and detecting inhibition of Fab I or Fab K; bactericides; fungicides; antibiotics; Stapylococcus
11/10/2005US20050250807 Neurotrophin antagonist compositions
11/10/2005US20050250792 Substituted piperidine compounds useful as modulators of chemokine receptor activity
11/10/2005US20050250790 Novel sulfonic acid derivatives
11/10/2005US20050250789 Hydroxamic acid derivatives as metalloprotease inhibitors
11/10/2005US20050250787 Pyrimidine compounds
11/10/2005US20050250782 Heterocyclic inhibitors of MEK and methods of use thereof
11/10/2005US20050250781 (1-piperidine-3-cyclopentane)-amide derivatives; antiinflammatory agent, antiallergen; autoimmune diseases; allergic rhinitis, dermatitis, conjunctivitis, asthma, rheumatoid arthritis and atherosclerosis
11/10/2005US20050250774 N-{2-[2-(3,4-Dimethoxy-phenyl)-ethoxy]-6-morpholin-4-yl-pyridin-4-yl}-N'-(1 H-indol-3-ylmethylene)-hydrazine; interleukin IL-12 overproduction-related disorder; antiinflammatory agent; autoimmune diseases: multiple sclerosis, sepsis, neuropathies, cirrhosis, hepatitis, diabetes, arthritis
11/10/2005US20050250771 Substituted indoles and their use as integrin antagonists
11/10/2005US20050250770 Fused heterocyclic compounds
11/10/2005US20050250768 Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
11/10/2005US20050250763 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
11/10/2005US20050250761 such as -Piperidin-1-yl-but-2-enoic acid [4(3-chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-yl]-amide, used as tyrosine kinase inhibitors, for the prevention of proliferative diseases, including cancer, atherosclerosis, restenosis, endometriosis and psoriasis
11/10/2005US20050250741 non-steroidal agonists and antagonists; 2-(2-ethylsulfanyl-1-hydroxy-1-methyl-ethyl)-6-trifluoromethyl-1H-indole-5--carbonitrile; anticarcinogenic; prostate carcinoma, benign prostatic hyperplasia (BPH), hirsutism, alopecia, anorexia nervosa, breast cancer, acne, AIDS, cachexia, as a male contraceptive
11/10/2005US20050250152 fluorescent derivatization reagents that label substances containing aldehydes, ketones, and similar functional groups, and their use in labeling glycoproteins and glycopeptides, nucleic acids and lipopolysaccharides, and other biomolecules
11/10/2005US20050249976 Material for organic electroluminescence devices and organic electroluminescence device using the material
11/10/2005US20050249675 Mucin synthesis inhibitors
11/10/2005US20050249669 Quadruplex stabilizer
11/10/2005US20050249662 Marked maleimide compounds, method for preparing same and use thereof for marking macromolecules
11/10/2005US20050249398 Rapid and robust 3D/3D registration technique
11/10/2005DE4317672B4 Homogene Schmelzmasse in Form einer festen Lösung aus Verbindungen mit sterisch gehinderten Aminogruppen, ein Verfahren zu deren Herstellung und deren Verwendung zum Stabilisieren von polymeren Natur- und Kunststoffen Homogeneous molten mass in the form of a solid solution of compounds with sterically hindered amino groups, a process for their preparation and their use for stabilizing polymeric natural products and plastics
11/10/2005DE102004019492A1 Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel Selected CGRP antagonists, processes for their preparation and their use as medicaments
11/10/2005CA2564589A1 Tri-substituted ureas as cytokine inhibitors
11/10/2005CA2564587A1 Tri-substituted ureas as cytokine inhibitors
11/10/2005CA2564564A1 Fluorinated 4-azasteroids as androgen receptor modulators
11/10/2005CA2564085A1 Heterocyclic amide compound and use thereof as an mmp-13 inhibitor
11/10/2005CA2563963A1 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor
11/10/2005CA2563222A1 Novel imidazoles
11/10/2005CA2562400A1 Novel phenantridine analogues and their uses as inhibitors of hyperproliferation of t cells and/or keratinocytes
11/10/2005CA2562176A1 Arylphenylamino-, arylphenylamide-, and arylphenylether-sulfide derivatives
11/09/2005EP1593677A2 Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes
11/09/2005EP1593664A1 Nitric esters derivatives of ferulic acid and sulindac with pharmaceutical activity
11/09/2005EP1592772A2 5ht7 antagonists and inverse agonists
11/09/2005EP1592686A1 Gyrase inhibitors and uses thereof
11/09/2005EP1592685A1 BIPHENYL DERIVATIVES HAVING &bgr; sb 2 /sb ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
1 ... 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 ... 1080